Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

11.30 -0.97 (-7.91%)
Delayed Quote Updated: 2:28 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
News headline image
AbCellera to Present at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
News headline image
This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
News headline image
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Q2 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
News headline image
"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday ↗
A week ago it was suggested that the AI/semiconductor stocks sector was oversold. The decline bottomed on Wednesday and by the close of business this past Friday the sector had rebounded nicely almost... 
Via Talk Markets
News headline image
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
News headline image
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD ↗
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
News headline image
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
News headline image
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI ↗
Although fraught with risk, these biotech exposures bring enormous upside potential. 
Via Talk Markets
News headline image
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th ↗
The global 
Via Talk Markets
News headline image
Down 57%, Is AbCellera Biologics a Buy on the Dip? ↗
Wall Street analysts say this drug developer can more than double your money. 
Via The Motley Fool
News headline image
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week ↗
The global 
Via Talk Markets
News headline image
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
News headline image
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In ↗
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗
Via Talk Markets
News headline image
3 Stock Gems Hiding in the Nasdaq ↗
If you don’t mind taking a risk in the discount section, these undervalued Nasdaq stocks just might surprise some folks. 
Via InvestorPlace
News headline image
5 Of 7 AI Categories Rose, Slightly,Over Past Week ↗
The 7 AI categories we track went up marginally (1.0%, on average) the second week of May, after having gone down 0.4% the previous week. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript ↗
ABCL earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 ↗
ABCL stock results show that AbCellera Biologics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
AbCellera Reports Q1 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.